Swiss perspectives in 10 languages

Genentech ordered to pay millions in damages

Genentech, the American subsidiary of Swiss pharmaceutical firm, Roche, has been ordered to pay an additional $200 million in punitive damages.

Two weeks ago, a Los Angeles jury told Genentech to pay $300 million to the California-based City of Hope cancer centre in a trial over drug royalty payments due under a 1976 contract.

Following Monday’s decision, the biotechnology company will now have to hand over a total of $500 million (SFr750 million) to the centre.

The cancer centre had accused Genentech of fraud for failing to pay cancer royalties on drugs sold that were made by companies to which the biotechnology firm had licensed the patents.

The Roche subsidiary – which announced it would appeal against the charges – said that it would nevertheless deduct $500 million from its second-quarter earnings to cover the payment.

Genentech shares rallied after Monday’s verdict, gaining $1.89, or nearly 6 per cent, to close at $34.84 on the New York Stock Exchange.

swissinfo with agencies

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR